bioAffinity Technologies (BIAF) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MaxCyte is the larger company by market cap ($105.3 million vs $6.6 million), about 16.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIAF | MXCT |
|---|---|---|
| Share price | $5.64 | $1.02 |
| Market cap | $6.58M | $105.27M |
| 1-day change | -8.44% | -1.92% |
| YTD return | — | -34.19% |
| 1-year return | — | -40.00% |
| 5-year return | — | -90.75% |
| EPS (TTM) | $-109.35 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $80.70 | $1.87 |
| 52-week low | $4.56 | $0.643 |
| Distance from 52-week high | -93.01% | -45.31% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +302.94% |
| Average volume | 3.67M | 668.82K |
| Shares outstanding | 1.17M | 103.21M |
| Employees | 57 | 91 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MaxCyte is about 16.0 times larger than bioAffinity Technologies by market value ($105.27M vs $6.58M).
About bioAffinity Technologies
BIAF stock →bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.
Healthcare · Diagnostics & Research · 57 employees
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Healthcare · Medical Devices · 91 employees
BIAF vs MXCT FAQ
Which is bigger, bioAffinity Technologies or MaxCyte?
MaxCyte (MXCT) is larger, with a market capitalization of $105.27M compared with $6.58M for bioAffinity Technologies (BIAF).
Are bioAffinity Technologies and MaxCyte in the same industry?
Both are in the Healthcare sector, but in different industries: Diagnostics & Research for bioAffinity Technologies and Medical Devices for MaxCyte.